Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Data Brief ; 27: 104057, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31687426

ABSTRACT

This article describes the chemical synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel Nurr1/NOT agonist. It is meant as a support to an article recently published in Bioorganic and Medicinal chemistry Letters and entitled "Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease" [1] and presenting the discovery, scope and potential of these new ligands of these nuclear receptors.

2.
Bioorg Med Chem Lett ; 29(7): 929-932, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30773432

ABSTRACT

In the course of a programme aimed at identifying Nurr1/NOT agonists for potential treatment of Parkinson's disease, a few hits from high throughput screening were identified and characterized. A combined optimization pointed to a very narrow and stringent structure activity relationship. A comprehensive program of optimization led to a potent and safe candidate drug displaying neuroprotective and anti-inflammatory activity in several in vitro and in vivo models.


Subject(s)
Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/pharmacology , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Parkinson Disease/drug therapy , Animals , Cell Line , Cricetinae , Drug Discovery , Gene Expression Regulation/drug effects , Homeodomain Proteins/metabolism , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Mice , Microglia/drug effects , Molecular Structure , Neurons/drug effects , Nuclear Receptor Subfamily 4, Group A, Member 2/genetics , Rats , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism
3.
Alzheimers Res Ther ; 10(1): 117, 2018 11 28.
Article in English | MEDLINE | ID: mdl-30486882

ABSTRACT

BACKGROUND: Anti-amyloid ß (Aß) immunotherapy represents a major area of drug development for Alzheimer's disease (AD). However, Aß peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified. Aß immunotherapy-related vasogenic edema has also been severely dose limiting for antibodies with effector functions binding vascular amyloid such as bapineuzumab. These two factors might have contributed to the limited efficacy demonstrated so far in clinical studies. METHODS: To address these limitations, we have engineered SAR228810, a humanized monoclonal antibody (mAb) with limited Fc effector functions that binds specifically to soluble protofibrillar and fibrillar forms of Aß peptide and we tested it together with its murine precursor SAR255952 in vitro and in vivo. RESULTS: Unlike gantenerumab and BAN2401, SAR228810 and SAR255952 do not bind to Aß monomers, low molecular weight Aß oligomers or, in human brain sections, to Aß diffuse deposits which are not specific of AD pathology. Both antibodies prevent Aß42 oligomer neurotoxicity in primary neuronal cultures. In vivo, SAR255952, a mouse aglycosylated IgG1, dose-dependently prevented brain amyloid plaque formation and plaque-related inflammation with a minimal active dose of 3 mg/kg/week by the intraperitoneal route. No increase in plasma Aß levels was observed with SAR255952 treatment, in line with its lack of affinity for monomeric Aß. The effects of SAR255952 translated into synaptic functional improvement in ex-vivo hippocampal slices. Brain penetration and decoration of cerebral amyloid plaques was documented in live animals and postmortem. SAR255952 (up to 50 mg/kg/week intravenously) did not increase brain microhemorrhages and/or microscopic changes in meningeal and cerebral arteries in old APPSL mice while 3D6, the murine version of bapineuzumab, did. In immunotolerized mice, the clinical candidate SAR228810 demonstrated the same level of efficacy as the murine SAR255952. CONCLUSION: Based on the improved efficacy/safety profile in non-clinical models of SAR228810, a first-in-man single and multiple dose administration clinical study has been initiated in AD patients.


Subject(s)
Alzheimer Disease/therapy , Amyloid beta-Peptides/immunology , Antibodies, Monoclonal, Humanized/administration & dosage , Brain/immunology , Immunotherapy/methods , Alzheimer Disease/immunology , Amyloid beta-Peptides/metabolism , Animals , Antibodies, Monoclonal, Humanized/adverse effects , Brain/metabolism , Excitatory Postsynaptic Potentials/immunology , Female , Hippocampus/immunology , Hippocampus/physiopathology , Humans , Immunotherapy/adverse effects , Male , Mice, Inbred C57BL , Optical Imaging , Primary Cell Culture , Risk Factors
4.
Bull Cancer ; 95 FMC Onco: F121-7, 2008 May 28.
Article in French | MEDLINE | ID: mdl-18511379

ABSTRACT

Medicine, as well as the whole society, should cope with a society getting older and older. Yet, to what extend are the peculiarities of elderly assessed and taken into account? And what about relationship and communication? Are elderly offered similar therapeutic projects and are they equally informed about them? Do they have, themselves, the same needs? Oncologists and the nursing staff encounter several peculiar difficulties while coping with elderly. These difficulties are not only due to a complicated medical situation of a multi-treated patient with along history of many other diseases, but also to strongly anchored received ideas that "it's easier to die when one is old" and that "it's better to preserve the patient by hiding his disease to him, and by lying to him about it, because it is worthless to tell him the truth". Yet, these ideas are not of any help. Wrong ideas, lack of information, means and trained manpower and sometimes of interest affect often negatively the patient's treatment outcome, and highlight, more than in any other patients, psychological, relational but also ethical thorny stakes. By focusing on the elderly peculiarities, while considering them as patients on their own, it would be possible to highlight these stakes and to better assess these touch by situations. This would help enhancing a better use of neuropsychology and psycho oncology and by that better tailor the therapeutic and nursing decisions as well as communication fashions in oncogeriatry.


Subject(s)
Neoplasms/psychology , Patient Education as Topic , Truth Disclosure , Aged , Aged, 80 and over , Attitude of Health Personnel , Humans , Neoplasms/diagnosis , Paternalism , Psychological Tests
5.
Am J Clin Oncol ; 27(3): 317-21, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15170156

ABSTRACT

Paclitaxel and vinorelbine are two drugs active against breast cancer. A phase II study was initiated with the aim of assessing the efficacy and feasibility of the combination. Twenty-six patients presenting with advanced breast cancer with a taxane- and vinorelbine-free line of chemotherapy were included and treated with vinorelbine (20 mg/m2 on D1, D15), followed by paclitaxel (175 mg/m2 on D1), every 3 weeks. A 48% (95% CI: 35-61) response rate was obtained in the 23 patients evaluable for response. Vinorelbine was administered on D15, as scheduled, in 72% of cycles. The main toxicity observed was grade III to IV neutropenia in 73% of patients. Febrile neutropenia was reported in three patients. Disease-free survival was 118 days, and overall median survival was 361 days. This combination of paclitaxel and vinorelbine is feasible and effective in patients with early relapse or previously treated with first-line chemotherapy for metastatic disease.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Vinblastine/analogs & derivatives , Adult , Breast Neoplasms/pathology , Female , Humans , Middle Aged , Neoplasm Metastasis , Paclitaxel/administration & dosage , Survival Analysis , Vinblastine/administration & dosage , Vinorelbine
SELECTION OF CITATIONS
SEARCH DETAIL
...